Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
With a market cap of 154.2B, Pfizer(PFE) trades at $27.09. The stock has a price-to-earnings ratio of 19.93 and currently yields dividends of 6.3%.
During the trading session on 2026-02-27, Pfizer(PFE) shares reached a daily high of $27.09 and a low of $27.00. At a current price of $27.09, the stock is +0.3% higher than the low and still -0.0% under the high.
Trading volume for Pfizer(PFE) stock has reached 43.8K, versus its average volume of 36.98M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.94 and a low of $20.92.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.94 and a low of $20.92.
PFE News
Pfizer secured exclusive commercialization rights to Sciwind's ecnoglutide in China for type 2 diabetes and potential obesity treatment. The company expanded i...
Pfizer Inc. (NYSE:PFE) shares are trending on Wednesday following the U.S. Food and Drug Administration’s (FDA) full approval of the BRAFTOVI combination regime...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) has ended a Phase 1b trial titled “A Phase 1b, Two-Part, Randomized, Do...
Analyst ratings
59%
of 29 ratingsMore PFE News
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is running a Phase 1 study in China called “A Phase 1, Randomized, Doub...
TD Cowen raised the firm’s price target on Novavax (NVAX) to $8 from $7 and keeps a Hold rating on the shares. The firm previewed its Q4 results and updated est...
As previously reported, RBC Capital initiated coverage of Pfizer (PFE) with an Underperform rating and $25 price target reflecting an “insurmountable” $15B-$20B...
Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive. Pfizer (PFE +1.18%) is one of the world's largest and most...
Pfizer recently reported positive progression-free survival data from Cohort 3 of its Phase 3 BREAKWATER trial, where BRAFTOVI plus cetuximab and FOLFIRI outper...
Advertisement Why Pfizer (PFE) is on investors’ radar today Pfizer (PFE) is back in focus as investors reassess the stock after a period of mixed returns, wit...
There are several solid prospects to choose from right now, but there's a reason I can't get these particular names out of my head. Does your portfolio need so...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.